The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3 ± 0.1°2θ and Raman shifts 943, 1173, 1527 and 1612 ± 5 cm-1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson’s disease.本發明描述一種三伸乙基四胺四氯化物之新穎結晶型，其具有相較於已知形式及相較於二氯化物鹽改良之室溫穩定性。該新穎結晶型之特徵為在XRPD光譜中在22.9、25.4、25.8、26.6、34.6及35.3±0.1° 2θ處及拉曼位移943、1173、1527及1612±5 cm-1處具有峰值。該三伸乙基四胺四氯化物之結晶型適用於治療威爾森氏病。
